2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $964M | $1.1B | $1.4B | $1.6B | $1.8B |
Cost of Revenue | $825M | $946M | $1.2B | $1.4B | $1.6B |
Gross Profit | $139M | $159M | $223M | $225M | $182M |
Gross Profit % | 14% | 14% | 16% | 14% | 10% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $78M | $71M | $105M | $121M | $0 |
Dep. & Amort. | $23M | $27M | $33M | $36M | $0 |
Def. Tax | -$770K | $9.2M | $14M | $11M | $0 |
Stock Comp. | $8.9M | $11M | $15M | $12M | $0 |
Chg. in WC | $35M | $13M | -$42M | -$29M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $4.7M | $2M | $4.7M | $8.1M | $14M |
ST Investments | $0 | $0 | $133K | $0 | $0 |
Cash & ST Inv. | $4.7M | $2M | $4.7M | $8.1M | $14M |
Receivables | $216M | $242M | $334M | $380M | $539M |
Inventory | $191M | $188M | $200M | $0 | $0 |
CBIZ reported strong first quarter results, with consolidated revenue increasing 70% year-over-year to $838 million, primarily due to the Markham acquisition; adjusted EBITDA doubled to $238 million, and adjusted diluted EPS rose 40% to $2.29 per share.
The company maintained its full-year 2025 adjusted EBITDA and adjusted EPS guidance, but widened its revenue guidance range to $2.8 billion–$2.95 billion due to ongoing economic and geopolitical uncertainty, particularly affecting non-recurring, project-based service lines (now 23% of revenue).
Integration of Markham is on schedule, with positive cultural alignment and collaboration; major focus areas ahead include technology system integration and unlocking $25 million in expected synergies, mostly to be realized in year two and beyond.
CBIZ continues to demonstrate resilience in its core recurring businesses (accounting, tax, benefits, and insurance), which performed in the mid-single digit growth range; government healthcare consulting posted strong growth and maintains a robust pipeline.
The company is prioritizing debt reduction (targeting leverage below 2.5x by end of 2026), remains disciplined on share repurchases, and is evaluating further M&A opportunities while managing integration costs (about $75 million expected in 2025, with facility optimization costs likely more pronounced in 2026).